Larvol ClinicDOSE ADJUSTMENT OUTCOMES IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA TREATED WITH IBRUTINIBTopic: Indolent and mantle-cell non-Hodgkin lymphoma — Clinical16h ago16h ago
Larvol ClinicRavulizumab provides long-term control of intravascular haemolysis and improves survival in…Background: Increasing genomic stratification coupledwith an evolving therapeutic landscape present challenges inthe choice of optimal…16h ago16h ago
Larvol ClinicEvaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin TreatmentStudy Overview16h ago16h ago
Larvol ClinicPrognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemiaAbstract16h ago16h ago
Larvol ClinicEQUE-CEL, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T THERAPY IN PATIENTS WITH HIGH RISK NEWLY…Title: CAR T cell therapy for the treatment of Multiple Myeloma16h ago16h ago
Larvol ClinicEfficacy and Safety Maintained in Adult PNH Patients Receiving Pegcetacoplan for Up to 3 YearsBlood cancer is often described as the hidden cancer. Despitebeing the United Kingdom’s third biggest cancer killer andfifth most common…16h ago16h ago
Larvol ClinicPROGRESSION TO MYELOFIBROSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIATopic: Myeloproliferative neoplasms — Clinical16h ago16h ago
Larvol ClinicNTI-TIM-3 ANTIBODY TQB2618 IN COMBINATION WITH PENPULIMABIN RELAPSED OR REFRACTORY CLASSIC HODGKIN…Topic: Hodgkin lymphoma — Clinical16h ago16h ago
Larvol ClinicPirtobrutinib and venetoclax ± rituximab in relapsed/refractory chronic lymphocyticopen_in_newIntroduction: PAX5::JAK2, a fusion driving 12% ofPhiladelphia-like acute lymphoblastic leukaemia (Ph-likeALL), confers aggressive disease…17h ago17h ago